Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Deals channel feed
Novo Nordisk offloads preclinical cancer candidate from $1.1B Forma buyout
3 years ago
Eli Lilly licenses early-stage non-opioid pain drug from Belgian biotech Confo
3 years ago
Ready to turn a new page, Landos Biopharma offloads former lead program to founder
3 years ago
R&D
Adamis announces merger four months after PhII/III miss
3 years ago
UK biotech hands off mid-stage C. difficile drug in up to $570M deal
3 years ago
Dr. Reddy's to buy Mayne Pharma’s US generics drug list for at least $90M
3 years ago
Pharma
Pfizer makes moves to acquire Seagen in potential $30B+ deal
3 years ago
Pharma
Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly
3 years ago
R&D
Roche and Blueprint agree to end collaboration for cancer drug Gavreto
3 years ago
Pharma
February freeze hits biotech as companies cut staff, thin pipelines and merge to survive
3 years ago
People
Adding to Claudin18.2 portfolio, AstraZeneca pays $63M cash for antibody-drug conjugate out of China
3 years ago
Former high-flying I/O biotech shelves lead drugs, chops staff and hands off the remnants in Nasdaq reshuffle
3 years ago
Bioregnum
Capsida and AbbVie make $70M upfront deal for genetic medicines in eye diseases
3 years ago
Pharma
Kinnate engineers $24M deal to win control of China joint venture back from OrbiMed, Foresite
3 years ago
China
Oxford Properties Group purchases Resilience manufacturing site for $125M
3 years ago
Pharma
Manufacturing
Merck hands Swedish biotech €10M cash to develop anti-inflammatory drugs
3 years ago
R&D
Biotech consolidation continues as Nasdaq-listed Erytech merges with phage therapy developer
3 years ago
The top 100 biotech VCs: Who's staying at the table and what do they want now?
3 years ago
Financing
Updated: J&J returns rights to early-stage, RNAi NASH candidate to Arrowhead
3 years ago
R&D
Cullinan Oncology drops $25M upfront for candidate from Harbour
3 years ago
R&D
Tillman Gerngross’ Amagma Therapeutics quietly ships antibodies to another biotech
3 years ago
Startups
With record-breaking mpox vaccine sales, Bavarian Nordic buys trio of shots from Emergent for $270M cash
3 years ago
Manufacturing
Sesen Bio reaches deal with investor group, paving way for Carisma merger
3 years ago
Financing
A Texas-based biotech becomes the latest to enter the SPAC scene
3 years ago
Financing
First page
Previous page
41
42
43
44
45
46
47
Next page
Last page